Atopic Dermatitis Clinical Trials in Indianapolis, Indiana
10 recruitingIndianapolis, Indiana
Showing 1–10 of 10 trials
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 4
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Atopic Dermatitis
Eli Lilly and Company200 enrolled66 locationsNCT07006792
Recruiting
Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 3
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche160 enrolled69 locationsNCT06863961
Recruiting
Phase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Atopic Dermatitis
Pfizer500 enrolled31 locationsNCT06807281
Recruiting
Phase 3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 2
A Study Evaluating TRIV-509 in Atopic Dermatitis
Atopic Dermatitis
Triveni Bio90 enrolled44 locationsNCT07167758
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Atopic Dermatitis
Galderma R&D1,000 enrolled108 locationsNCT06988605
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled97 locationsNCT05995964